The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Valneva’s single-dose chikungunya vaccine for use in adults. Ixchiq is now the first vaccine approved in the UK to prevent ...
India experiences the world’s absolute burden of at least 11 NTDs, including hookworm, dengue, lymphatic filariasis, leprosy, kala-azar, and rabies, representing the highest number of cases worldwide ...
Chikungunya also increases one's risk of developing arthritis, making its prevention ... demonstrating the significance of studying entire viral families. In late 2024, an epidemic in the Congo ...
Chikungunya fever is a zoonotic viral disease transmitted by infected Aedes spp ... Regarding clinical characteristics, chronic chikungunya arthritis (CCA) can mimic many rheumatic conditions, being ...
Feb. 18, 2025 – The FDA has approved a new vaccine to protect against chikungunya. This first-of-its-kind shot is approved to prevent this viral disease in people ages 12 and older. Chikungunya ...
The Danish company’s chikungunya vaccine, Vimkunya, has now crossed the FDA finish line, heating up the competition with Valneva by countering with a label that covers a broader population.
Viral infections may manifest as acute or chronic arthritis. Joint involvement arises from either direct infection of the joint, through an immunological response directed towards the virus or ...
According to the World Health Organization (WHO), chikungunya is a mosquito-borne viral disease that causes fever, swelling, and joint pain. Like dengue, patients may experience muscle pain, headache, ...
Today, however, in an era of increasingly common foreign travel combined with our recognition that viral epidemics can spread precipitously in our global community, this role might be about to change.